StockData
Surrozen, Inc./DE logo

Surrozen, Inc./DE (SRZN) stock

SRZNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 5/30
$31.74+1.76 (+5.87%)

Close on Nov 18, 2026Market cap $373.06MP/E –Yield –

Surrozen revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Surrozen's revenue for the twelve months ending Jun 30, 2026 was $11.51M, down 8.8% year over year. For fiscal 2025 it was $3.48M, down 67.4% from the year before. The highest annual figure on record is $12.50M in fiscal 2022.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$3.48M-67.4%
FY2024Dec 31, 2024$10.66M–
FY2023Dec 31, 2023$0-100.0%
FY2022Dec 31, 2022$12.50M–
FY2021Dec 31, 2021$0–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$5.00M+408.6%
Q1 FY2026Mar 31, 2026$5.00M+408.6%
Q4 FY2025Dec 31, 2025$528.00K-19.4%
Q3 FY2025Sep 30, 2025$983.00K-90.2%
Q2 FY2025Jun 30, 2025$983.00K–
Q1 FY2025Mar 31, 2025$983.00K–
Q4 FY2024Dec 31, 2024$655.00K–
Q3 FY2024Sep 30, 2024$10.00M–
Q4 FY2023Dec 31, 2023$0–
Q3 FY2023Sep 30, 2023$0–

More Surrozen figures

See a number that looks wrong?